More News! 6 Jun 2019 Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase IIb trial. The trial had enrolled 179 patients with hidradenitis suppurativa, an incurable condition causing painful lumps on the skin. By the 16th week of […] June 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2019 Highlights from European Biotech at ASCO 2019 European biotech companies gathered in Chicago, USA, to share the latest advances in cancer research at the biggest cancer conference of the year, ASCO 2019. This year’s conference has drawn fewer big blockbuster headlines than other years, but there was plenty to see nonetheless. There were results from many different clinical trials by big pharma […] June 5, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2019 Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine The market is in sight for the first potential vaccine for the chikungunya virus, as the company Themis Bioscience will receive up to €18.7M ($21M) in non-dilutive funding to finance the vaccine’s phase III development. The money will cover most of the costs of the phase III trial, which Themis expects to begin later this […] June 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2019 First Gene Therapy for Beta Thalassemia Approved in Europe The US biotech company bluebird bio has obtained EU conditional market approval for a gene therapy that could remove the need for blood transfusions for people with the blood disorder beta-thalassemia. Called Zynteglo, the gene therapy is aimed at treating people with beta-thalassemia who are over 12 years of age and have any but the […] June 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jun 2019 Belgian and US Biotechs Team up to Reduce CAR T Side Effects The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR T-cell therapies in patients to better manage side effects. CAR T-cell therapies have revolutionized the way we treat cancer. Instead of giving the patient a classical drug, companies can inject them with living, genetically engineered cells that kill cancer cells. […] June 3, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jun 2019 Dutch Company Raises €28M to Push Cancer Cell Therapy to European Market The Dutch Kiadis Pharma has raised €27.6M in a private placement to fund the clinical development of immune cell therapies treating blood cancer. The money will fund phase III trials of Kiadis’ lead candidate cell therapy for blood cancer, aimed to get European approval by the end of 2019. In addition, the cash will boost […] June 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 31 May 2019 This Biotech Treats a Neurological Autoimmune Disorder Using DNA We’re jumping into Poland this week. Pure Biologics is a biotech based in Wrocław developing DNA molecules that could treat the incurable neurological condition Devic’s disease with fewer side effects than existing treatments. Mission: To develop a treatment that makes an existing treatment for Devic’s disease, plasmapheresis, more targeted and with fewer side effects than […] May 31, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2019 After Unexpected Setback, GenSight Seeks Approval for Blindness Gene Therapy The French biotech GenSight will apply for regulatory approval for its gene therapy despite the treatment unexpectedly resulting in the improvement of the eyes treated with a placebo in a phase III trial. GenSight is developing a gene therapy designed to treat progressive vision loss caused by the rare genetic condition Leber hereditary optic neuropathy. […] May 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2019 €60M Investment to Boost Oxford Biomedica’s Gene and Cell Therapies The Danish investor Novo Holdings is handing Oxford Biomedica up to €60.6M (£53.5M) to develop gene and cell therapies treating cancer and genetic blindness. The investment will bag Novo Holdings a stake of up to 10.1% in the UK biotech. Oxford Biomedica will use the money to repay a loan totalling €49M ($55M) from the […] May 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 28 May 2019 Nanomedicine Company Launches in France to Improve Drug Safety The French nanomedicine biotech Nanobiotix is spinning out a subsidiary company developing nanoparticles that can enhance a drug’s effectiveness and decrease side effects. Called Curadigm, the spinout will be developing nanotechnology with the potential to make low drug doses more effective at treating different conditions, which could make treatments cheaper and with fewer side effects […] May 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2019 Viral Vaccines Could Be Weapons Against Alzheimer’s Disease Scientists in Sweden have found that some viruses can increase the buildup of protein ‘plaques’ linked to Alzheimer’s disease, a discovery that could lead to new vaccines treating the condition. According to Kariem Ezzat, one of the lead researchers based in Stockholm University, the group is looking for industrial collaborators to develop vaccines against viruses […] May 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 24 May 2019 French Pharma Acquires Israeli Microalgae Biotech The French pharmaceutical manufacturer Solabia has acquired the Israeli biotech Algatech, which grows microalgae to produce bio-sourced food additives. The financial details of the acquisition were undisclosed. The incoming financial backing from Solabia will fuel the expansion of Algatech’s manufacturing muscle and research programs, which are based in the deserts of Israel. The acquisition represents […] May 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email